Drug Solutions Podcast: 2022 Bio/pharma Trends: US-Based Suppliers, Digitization, and Sustainability
In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.
Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.
In this episode, Chris Spivey, Editorial Director, and Meg Rivers, Senior Editor, interview industry experts to discuss 2022 trends along with a few trends that emerged in 2021, specifically:
- Biomanufacturing trends from 2021
- The demand for US-based suppliers in 2022
- Ensuring resources in the supply chain, including collaborations with competitors
- Digitizing and remote work
- Sustainability in APIs; API and drug product interface; API and excipient trends
- Increased interest in modeling services
- Importance of new cell therapies
Interviews featuring:
- Peter Walters, Director of ATMP, CRB
- Yvonne Duckworth, Automation Engineer, CRB
- Cary Martin, VP of Marketing, August Bioservices
- Gabe Longoria, Chief Commercial Officer, Astrea Bioseparations
- Merrilee Whitney, Head of Biocontinuum Platform, MilliporeSigma (the Life Science business of Merck KGaA, Darmstadt, Germany)
- Helen Anderson, Commercial Lead, USA, Aspen
- San Kiang, CTO, Porton Pharmatech/J-Star Research
- Anil Kane, Global Head of Technical Scientific Affairs, Pharma Services, Thermo Fisher Scientific
- Matthias Bucerius, Head of Actives and Formulation, MilliporeSigma (the Life Science business of Merck KGaA, Darmstadt, Germany)
- Jeff Woodhead, Senior Scientist, Simulations Plus
- Gregory Lane, PhD, Senior Research Investigator, Bristol Myers Squibb
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
